^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IL23 elevation

    i
    Other names: IL23A, Interleukin 23 Subunit Alpha, SGRF, IL23P19, IL-23A, IL-23, P19, Interleukin-Six, G-CSF Related Factor, Interleukin 23, Alpha Subunit P19, Interleukin-23 Subunit Alpha, Interleukin-23 Subunit P19, IL-23 Subunit Alpha, IL-23p19, IL-23-A, JKA3 Induced Upon T-Cell Activation, Interleukin 23 P19 Subunit
    Entrez ID:
    51561
    1year
    Off-label dermatologic uses of IL-23 inhibitors. (PubMed, J Dermatolog Treat)
    While IL-23 inhibitors, which include guselkumab, tildrakizumab, and risankizumab, are currently FDA-approved solely for the treatment of psoriasis, several other inflammatory skin conditions have been associated with elevated IL-23 levels. Current literature suggests that IL-23 inhibitors may be effective in treating these conditions due to shared pathophysiologic pathways with psoriasis. Although these results are promising, further research through large-scale, randomized clinical trials is needed to further evaluate the efficacy and safety of IL-23 inhibitors in treating these off-label conditions.
    Clinical • Review • Journal
    |
    IL23A (Interleukin 23 Subunit Alpha)
    |
    IL23 elevation
    |
    Ilumya (tildrakizumab-asmn)